Leerink Partners Reiterates Outperform Rating on AnaptysBio (ANAB)

October 3, 2024 8:19 AM UTC Send to a Friend
Leerink Partners analyst David Risinger reiterated an Outperform rating and $35.00 price target on AnaptysBio (NASDAQ: ANAB)The analyst comments "We ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login